Perspectives on plasmid-based gene therapy: challenges for the product and the process
Related Experiment Video
Updated: Sep 26, 2026

Development of Mesenchymal Stem Cell Membrane-Enveloped Nanovesicles for Enhanced Gene Delivery
Published on: February 17, 2026
1Chemical Engineering Department, Villanova University, 318 White Hall, 800 Lancaster Ave, Villanova, PA 19085, USA. william.j.kelly@villanova.edu
Abstract:
Clinical trials for gene-therapy products began in the 1990s. Currently, most of the 630 completed or on-going trials are in Phase I and II. Because of the safety issues surrounding the use of viral vectors, approx. 25% of the ongoing clinical trials use DNA plasmids to carry the corrective gene (http://www.wiley.co.uk/genmed). The purpose of this perspective (and this issue) is to highlight some of the unique technical challenges and potential solutions associated with the manufacture and expression of a plasmid-based gene-therapy product.
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Bacterial Transformation
Gene Therapy
Upstream Processing
What is Genetic Engineering?

